Research programme: microbial immunotherapies - Salspera
Latest Information Update: 20 Jan 2021
At a glance
- Originator Salspera
- Class Antineoplastics; Bacteria; Gene therapies; Immunotherapies
- Mechanism of Action Bacteria replacements; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 20 Jan 2021 Research programme: microbial immunotherapies - Salspera is available for licensing as of 20 Jan 2021. https://www.salspera.com/
- 20 Jan 2021 Early research in Solid tumours in USA (PO) before January 2021 (Salspera's pipeline, January 2021)